CN101062032A - Sulbactam sodium bacteriophage complex and the preparing method thereof - Google Patents
Sulbactam sodium bacteriophage complex and the preparing method thereof Download PDFInfo
- Publication number
- CN101062032A CN101062032A CN 200610075961 CN200610075961A CN101062032A CN 101062032 A CN101062032 A CN 101062032A CN 200610075961 CN200610075961 CN 200610075961 CN 200610075961 A CN200610075961 A CN 200610075961A CN 101062032 A CN101062032 A CN 101062032A
- Authority
- CN
- China
- Prior art keywords
- sulbactam sodium
- liposome
- sodium
- weight
- bacteriophage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention discloses a diastole bar apron sodium antibiotics and preparing craft, which is characterized by the following: allocating with mass ratio as 100-400 antibiotics, 100-400 diastole bar apron sodium, 10-300 liposome and 10-300 polyvinyl pyrrolidon; keeping the drug-effect of common diastole bar apron sodium antibiotics compound; prolonging nullifying half-decay time of the antibiotics; adding antioxidant into composite drug; increasing stability of the drug. This invention can prolongs the effective time of the drug.
Description
Technical field
The present invention relates to a kind of sulbactam sodium bacteriophage complex and preparation technology thereof.
Background technology
The application of antibiotics has thoroughly overcome the situation that bacterial disease is difficult to treat.But because the speed of mutation of antibacterial is too fast, along with the widespread adoption of antibiotic medicine, increasing antibacterial produces drug resistance to the antibiotics of clinical practice, has had a strong impact on the therapeutic effect of bacterial disease.In order to solve the problem of bacterial drug resistance, adopt antibiotics and beta-lactamase inhibitor sulbactam sodium (sulbactam) use in conjunction clinically, obtained good effect.On this basis, a large amount of antibiotics and sulbactam sodium composition of medicine also begin to occur.
Current antibiotics and sulbactam sodium composition of medicine have just solved the proportioning problem of antibiotics and sulbactam sodium, thereby have solved antibiotics by the problem of beta-lactam enzymatic degradation.But, do not consider that the beta-lactam structure is easily oxidized and influence the factor of its curative effect.And the novel substance that the sulbactam sodium oxidation produces also can produce certain toxic and side effects to human body.
Current antibiotics and sulbactam sodium composition of medicine are not considered the difference of the half-life of antibiotics and sulbactam sodium yet.There is bigger difference in the elimination half-life of antibiotics and sulbactam sodium, and wherein, the elimination half-life of avocin only is the 50-60% of sulbactam sodium sodium half-life.Because the difference of half-life causes the asynchronous of its drug effect, causes the inharmonious of medication.
Current antibiotics and sulbactam sodium composition of medicine are in clinical use, and the 70-80% in the medicine is directly excretory by kidney, and kidney has been produced stronger toxicity injury.
Summary of the invention
It is bigger to eliminate the half-life difference at the easy oxidation of above-mentioned sulbactam sodium, antibiotics and the sulbactam sodium of current antibiotics and the existence of sulbactam sodium composition of medicine, medicine produces problems such as injury easily to kidney in the process renal excretion, the invention provides a kind of sulbactam sodium bacteriophage complex, effectively to address the above problem.
Technical scheme of the present invention is as follows:
The invention provides a kind of sulbactam sodium bacteriophage complex, the feedstock production of following parts by weight forms:
'beta '-lactam antibiotic 100-400;
Sulbactam sodium 100-400;
Liposome 10-300;
Polyvinylpyrrolidone 10-300.
As prioritization scheme, described sulbactam sodium bacteriophage complex is formed by the feedstock production of following parts by weight:
'beta '-lactam antibiotic 100-400;
Sulbactam sodium 100-400;
Liposome 15-250;
Polyvinylpyrrolidone 15-250.
Described sulbactam sodium bacteriophage complex also includes antioxidant.
Described antioxidant be meant reduced glutathion or alpha-mercapto N-Propionylglycine and glucurolactone mixture etc. the weight mixture, the reduced glutathion consumption is the 0.5-4 parts by weight, and the consumption of alpha-mercapto N-Propionylglycine and glucurolactone mixture is the 100-140 parts by weight.
The diameter of described liposome is below 150nm.
Described 'beta '-lactam antibiotic is meant avocin, Amoxicillin Sodium and cefoperazone sodium.
In described sulbactam sodium bacteriophage complex, the phospholipid of liposome is with the form and the polyvinylpyrrolidone complexation of hydrogen bond, thereby makes the liposome can coagulation sedimentation when lyophilization, and lyophilized powder can be dissolved into dispersion completely again.
The diameter of described liposome is below 150nm.
The 10-40% that the sulbactam sodium of parcel and antibiotics account for sulbactam sodium and antibiotics gross weight respectively in the liposome.
As prioritization scheme, the 20-30% that the sulbactam sodium of parcel and antibiotics account for sulbactam sodium and antibiotics gross weight respectively in the liposome.
The present invention also provides the preparation technology of described sulbactam sodium bacteriophage complex, and step is as follows:
1) gets described amount liposome, be dissolved in the phosphate buffer;
2) described amount antibiotic and described amount sulbactam sodium are joined in the liposome solutions, dissolve under the ultrasonic stirring, regulate pH value between 5.0-7.0;
3) ultrasonic stirring adds described amount antioxidant and described weight northylen ketopyrrolidine, and dissolving repeats ultrasonic Treatment, and obtaining described amount antibiotic and described amount sulbactam sodium is the solution of 10-40% by the liposome rate;
4) with behind the 0.22um membrane filtration of step 3) gained solution usefulness aperture, lyophilization obtains lyophilized powder.
As prioritization scheme, the preparation technology of described sulbactam sodium bacteriophage complex, step is as follows:
1) gets described amount liposome, be dissolved in the phosphate buffer;
2) described amount antibiotic and described amount sulbactam sodium are joined in the liposome solutions, dissolve under the ultrasonic stirring, regulate pH value between 5.0-7.0;
3) ultrasonic stirring adds described amount antioxidant and described weight northylen ketopyrrolidine, and dissolving repeats ultrasonic Treatment, and obtaining described amount antibiotic and described amount sulbactam sodium is the solution of 20-30% by the liposome rate;
4) with behind the 0.22um membrane filtration of step 3) gained solution usefulness aperture, lyophilization obtains lyophilized powder.
The technique effect that the present invention realized is as follows:
Sulbactam sodium bacteriophage complex provided by the present invention had both kept the drug effect of common sulbactam sodium bacteriophage complex, had increased again that liposome is peculiar to be easy to characteristics such as permeates cell membranes, and had prolonged the elimination half-life of antibiotics.Owing to also in combination drug, added antioxidant, further improved stability of drug.Make that prolonged the effective acting time of medicine, reduced the anaphylactoid generation that repeated drug taking causes simultaneously.Because the ingredient of parcel effectively reduces the toxic action of medicine to kidney not directly through renal excretion in the liposome.
The specific embodiment
The preparation liposome is standby:
1) getting soybean phospholipid or lecithin is scattered in the phosphate buffer (pH5.0-7.0, concentration are 0.01mol/L), the time of ultrasonic Treatment should be less than 45 minutes, treatment temperature should be lower than 35 ℃, and ultrasonic power obtains blank liposome solution less than 40-60W/10L.
2), obtain the blank liposome solution of diameter below 150nm with the blank liposome solution 150nm membrane filtration of step 1) gained.
3) repeating step 1) and step 2), up to step 2) in the gained liposome solutions, the liposome of diameter between 100-150nm accounts for more than 50% of liposome total amount in the solution.
Embodiment 1:
It is laboratory animal that present embodiment adopts the mice of respiratory tract infection disease model, mixture with sulbactam sodium bacteriophage complex provided by the present invention and 100g avocin/400g sulbactam sodium compares experiment respectively, the contrast grouping, 100 every group, body weight 18-20g.
The raw material that present embodiment adopted and each raw materials in part by weight are as follows:
Avocin 100;
Sulbactam sodium 400;
Liposome 15;
Polyvinylpyrrolidone 15;
Reduced glutathion 4.
Preparation method is as follows:
1) gets the above-mentioned liposome solutions that contains the 15g liposome.
2) 100g avocin and 400g sulbactam sodium are joined in the liposome solutions, (time of ultrasonic Treatment should be less than 45 minutes for ultrasonic stirring, treatment temperature should be lower than 35 ℃, and ultrasonic power is less than 40-60W/10L) dissolving down, regulate pH value between 5.0-7.0.
3) (time of ultrasonic Treatment should be less than 45 minutes for limit usefulness ultrasonic stirring, treatment temperature should be lower than 35 ℃, ultrasonic power is less than 40-60W/10L), the limit adds 4g reduced glutathion and 15g polyvinylpyrrolidone, dissolving, obtaining avocin and sulbactam sodium is the solution of 20-30% by the liposome rate.
4) with behind the step 3) gained solution usefulness 0.22um membrane filtration, lyophilization obtains lyophilized powder.
5) lyophilized powder is distributed into aliquot
Usage and dosage:
Is 100mg/kg by avocin weight with being subjected to medicine mice weight ratio, gets above-mentioned lyophilized powder, is dissolved in the normal saline of 4 times of weight, adopts the intravenous injection mode to the experiment mice administration.Be administered twice every day.Treatment cycle is 7 days.Avocin/sulbactam sodium mixture usage and dosage is with pharmaceutical standards of the present invention, intravenous injection, and every day three times, treatment cycle is 7 days.
Result of use is as follows:
| Avocin/sulbactam sodium mixture | 75 | 3 | 21 | 19 |
Embodiment 2:
It is laboratory animal that present embodiment adopts the mice of soft tissue infection's disease model, compare experiment with sulbactam sodium bacteriophage complex provided by the present invention and 400g Amoxicillin Sodium/200g sulbactam sodium mixture respectively, the contrast grouping, 100 every group, body weight 18-20g.
The raw material that present embodiment adopted and each raw materials in part by weight are as follows:
Amoxicillin Sodium 400;
Sulbactam sodium 200;
Liposome 250;
Polyvinylpyrrolidone 250;
Reduced glutathion 0.5.
Preparation method is as follows:
1) gets the above-mentioned liposome solutions that contains the 250g liposome.
2) 400g Amoxicillin Sodium and 200g sulbactam sodium are joined in the liposome solutions, (time of ultrasonic Treatment should be less than 45 minutes for ultrasonic stirring, treatment temperature should be lower than 35 ℃, and ultrasonic power is less than 40-60W/10L) dissolving down, regulate pH value between 5.0-7.0.
3) (time of ultrasonic Treatment should be less than 45 minutes for limit usefulness ultrasonic stirring, treatment temperature should be lower than 35 ℃, ultrasonic power is less than 40-60W/10L), the limit adds 0.5g reduced glutathion and 250g polyvinylpyrrolidone, dissolving, obtaining Amoxicillin Sodium and sulbactam sodium is the solution of 10-20% by the liposome rate.
4) with behind the step 3) gained solution usefulness 0.22um membrane filtration, lyophilization obtains lyophilized powder.
5) lyophilized powder is distributed into aliquot
Usage and dosage:
Is 100mg/kg by Amoxicillin Sodium weight with being subjected to medicine mice weight ratio, gets above-mentioned lyophilized powder, is dissolved in the normal saline of 4 times of weight, adopts the intravenous injection mode to the experiment mice administration.Be administered twice every day.Treatment cycle is 7 days.Avocin/sulbactam sodium mixture usage and dosage is with pharmaceutical standards of the present invention, intravenous injection, and every day three times, treatment cycle is 7 days.
Result of use is as follows:
Embodiment 3:
It is laboratory animal that present embodiment adopts the mice of the sick disease model of wound infection, compare experiment with sulbactam sodium bacteriophage complex provided by the present invention and 200g cefoperazone sodium/100g sulbactam sodium mixture respectively, the contrast grouping, 100 every group, body weight 18-20g.
The raw material that present embodiment adopted and each raw materials in part by weight are as follows:
Cefoperazone sodium 200;
Sulbactam sodium 100;
Liposome 15;
Polyvinylpyrrolidone 15;
Reduced glutathion 2.
Preparation method is as follows:
1) gets the above-mentioned liposome solutions that contains the 15g liposome.
2) 200g cefoperazone sodium and 100g sulbactam sodium are joined in the liposome solutions, (time of ultrasonic Treatment should be less than 45 minutes for ultrasonic stirring, treatment temperature should be lower than 35 ℃, and ultrasonic power is less than 40-60W/10L) dissolving down, regulate pH value between 5.0-7.0.
3) (time of ultrasonic Treatment should be less than 45 minutes for limit usefulness ultrasonic stirring, treatment temperature should be lower than 35 ℃, ultrasonic power is less than 40-60W/10L), the limit adds 2g reduced glutathion and 15g polyvinylpyrrolidone, dissolving, obtaining cefoperazone sodium and sulbactam sodium is the solution of 10-20% by the liposome rate.
4) with behind the step 3) gained solution usefulness 0.22um membrane filtration, lyophilization obtains lyophilized powder.
5) lyophilized powder is distributed into aliquot
Usage and dosage:
Is 100mg/kg by cefoperazone sodium weight with being subjected to medicine mice weight ratio, gets above-mentioned lyophilized powder, is dissolved in the normal saline of 4 times of weight, adopts the intravenous injection mode to the experiment mice administration.Be administered twice every day.Treatment cycle is 7 days.Avocin/sulbactam sodium mixture usage and dosage is with pharmaceutical standards of the present invention, intravenous injection, and every day three times, treatment cycle is 7 days.
Result of use is as follows:
Embodiment 4:
It is laboratory animal that present embodiment adopts the mice of the sick disease model of wound infection, compare experiment with sulbactam sodium bacteriophage complex provided by the present invention and 400g avocin/100g sulbactam sodium mixture respectively, the contrast grouping, 100 every group, body weight 18-20g.
The raw material that present embodiment adopted and each raw materials in part by weight are as follows:
Avocin 400;
Sulbactam sodium 100;
Liposome 250;
Polyvinylpyrrolidone 250;
Reduced glutathion 1.
Preparation method is as follows:
1) gets the above-mentioned liposome solutions that contains the 250g liposome.
2) 400g avocin and 100g sulbactam sodium are joined in the liposome solutions, (time of ultrasonic Treatment should be less than 45 minutes for ultrasonic stirring, treatment temperature should be lower than 35 ℃, and ultrasonic power is less than 40-60W/10L) dissolving down, regulate pH value between 5.0-7.0.
3) (time of ultrasonic Treatment should be less than 45 minutes for limit usefulness ultrasonic stirring, treatment temperature should be lower than 35 ℃, ultrasonic power is less than 40-60W/10L), the limit adds 1g reduced glutathion and 250g polyvinylpyrrolidone, dissolving, obtaining avocin and sulbactam sodium is the solution of 20-40% by the liposome rate.
4) with behind the step 3) gained solution usefulness 0.22um membrane filtration, lyophilization obtains lyophilized powder.
5) lyophilized powder is distributed into aliquot
Usage and dosage:
Is 100mg/kg by avocin weight with being subjected to medicine mice weight ratio, gets above-mentioned lyophilized powder, is dissolved in the normal saline of 4 times of weight, adopts the intravenous injection mode to the experiment mice administration.Be administered twice every day.Treatment cycle is 7 days.Avocin/sulbactam sodium mixture usage and dosage is with pharmaceutical standards of the present invention, intravenous injection, and every day three times, treatment cycle is 7 days.
Result of use is as follows:
Embodiment 5:
It is laboratory animal that present embodiment adopts the mice of soft tissue infection's disease model, compare experiment with sulbactam sodium bacteriophage complex provided by the present invention and 100g avocin/400g sulbactam sodium mixture respectively, the contrast grouping, 100 every group, body weight 18-20g.
The raw material that present embodiment adopted and each raw materials in part by weight are as follows:
Avocin 100;
Sulbactam sodium 400;
Liposome 10;
Polyvinylpyrrolidone 10;
Reduced glutathion 4.
Preparation method is as follows:
1) gets the above-mentioned liposome solutions that contains the 10g liposome.
2) 100g avocin and 400g sulbactam sodium are joined in the liposome solutions, (time of ultrasonic Treatment should be less than 45 minutes for ultrasonic stirring, treatment temperature should be lower than 35 ℃, and ultrasonic power is less than 40-60W/10L) dissolving down, regulate pH value between 5.0-7.0.
3) (time of ultrasonic Treatment should be less than 45 minutes for limit usefulness ultrasonic stirring, treatment temperature should be lower than 35 ℃, ultrasonic power is less than 40-60W/10L), the limit adds 4g reduced glutathion and 10g polyvinylpyrrolidone, dissolving, obtaining avocin and sulbactam sodium is the solution of 10-20% by the liposome rate.
4) with behind the step 3) gained solution usefulness 0.22um membrane filtration, lyophilization obtains lyophilized powder.
5) lyophilized powder is distributed into aliquot
Usage and dosage:
Is 100mg/kg by avocin weight with being subjected to medicine mice weight ratio, gets above-mentioned lyophilized powder, is dissolved in the normal saline of 4 times of weight, adopts the intravenous injection mode to the experiment mice administration.Be administered twice every day.Treatment cycle is 7 days.Avocin/sulbactam sodium mixture usage and dosage is with pharmaceutical standards of the present invention, intravenous injection, and every day three times, treatment cycle is 7 days.
Result of use is as follows:
Embodiment 6:
It is laboratory animal that present embodiment adopts the mice of respiratory tract infection disease model, compare experiment with sulbactam sodium bacteriophage complex provided by the present invention and 100g avocin/100g sulbactam sodium mixture respectively, the contrast grouping, 100 every group, body weight 18-20g.
The raw material that present embodiment adopted and each raw materials in part by weight are as follows:
Avocin 100;
Sulbactam sodium 100;
Liposome 300;
Polyvinylpyrrolidone 300;
Add in addition alpha-mercapto N-Propionylglycine and glucurolactone mixture etc. weight mixture 100 weight portions.
Preparation method is as follows:
1) gets the above-mentioned liposome solutions that contains the 300g liposome.
2) 100g avocin and 100g sulbactam sodium are joined in the liposome solutions, dissolving is regulated pH value between 5.0-7.0.
3) (time of ultrasonic Treatment should be less than 45 minutes for limit usefulness ultrasonic stirring, treatment temperature should be lower than 35 ℃, ultrasonic power is less than 40-60W/10L), the limit add 100g alpha-mercapto N-Propionylglycine and glucurolactone mixture etc. weight mixture and 300g polyvinylpyrrolidone, dissolving, obtaining avocin and sulbactam sodium is the solution of 20-40% by the liposome rate.
4) with behind the step 3) gained solution usefulness 0.22um membrane filtration, lyophilization obtains lyophilized powder.
5) lyophilized powder is distributed into aliquot
Usage and dosage:
Is 100mg/kg by avocin weight with being subjected to medicine mice weight ratio, gets above-mentioned lyophilized powder, is dissolved in the normal saline of 4 times of weight, adopts the intravenous injection mode to the experiment mice administration.Be administered twice every day.Treatment cycle is 7 days.Avocin/sulbactam sodium mixture usage and dosage is with pharmaceutical standards of the present invention, intravenous injection, and every day three times, treatment cycle is 7 days.
Result of use is as follows:
Embodiment 7:
It is laboratory animal that present embodiment adopts the mice of respiratory tract infection disease model, compare experiment with sulbactam sodium bacteriophage complex provided by the present invention and 400g avocin/400g sulbactam sodium mixture respectively, the contrast grouping, 100 every group, body weight 18-20g.
The raw material that present embodiment adopted and each raw materials in part by weight are as follows:
Avocin 400;
Sulbactam sodium 400;
Liposome 300;
Polyvinylpyrrolidone 300;
Add in addition alpha-mercapto N-Propionylglycine and glucurolactone mixture etc. weight mixture 120 weight portions.
Preparation method is as follows:
1) gets the above-mentioned liposome solutions that contains the 300g liposome.
2) 400g avocin and 400g sulbactam sodium are joined in the liposome solutions, (time of ultrasonic Treatment should be less than 45 minutes for ultrasonic stirring, treatment temperature should be lower than 35 ℃, and ultrasonic power is less than 40-60W/10L) dissolving down, regulate pH value between 5.0-7.0.
3) (time of ultrasonic Treatment should be less than 45 minutes for limit usefulness ultrasonic stirring, treatment temperature should be lower than 35 ℃, ultrasonic power is less than 40-60W/10L), the limit add 120g alpha-mercapto N-Propionylglycine and glucurolactone mixture etc. weight mixture and 300g polyvinylpyrrolidone, dissolving, obtaining avocin and sulbactam sodium is the solution of 20-30% by the liposome rate.
4) with behind the step 3) gained solution usefulness 0.22um membrane filtration, lyophilization obtains lyophilized powder.
5) lyophilized powder is distributed into aliquot
Usage and dosage:
Is 100mg/kg by avocin weight with being subjected to medicine mice weight ratio, gets above-mentioned lyophilized powder, is dissolved in the normal saline of 4 times of weight, adopts the intravenous injection mode to the experiment mice administration.Be administered twice every day.Treatment cycle is 7 days.Avocin/sulbactam sodium mixture usage and dosage is with pharmaceutical standards of the present invention, intravenous injection, and every day three times, treatment cycle is 7 days.
Result of use is as follows:
Claims (10)
1. sulbactam sodium bacteriophage complex, it is characterized in that: the feedstock production by following parts by weight forms:
'beta '-lactam antibiotic 100-400;
Sulbactam sodium 100-400;
Liposome 10-300;
Polyvinylpyrrolidone 10-300.
2. sulbactam sodium bacteriophage complex according to claim 1 is characterized in that: the feedstock production by following parts by weight forms:
'beta '-lactam antibiotic 100-400;
Sulbactam sodium 100-400;
Liposome 15-250;
Polyvinylpyrrolidone 15-250.
3. according to claim 1 or 2 any described sulbactam sodium bacteriophage complexes, it is characterized in that: described sulbactam sodium bacteriophage complex also includes antioxidant.
4. sulbactam sodium bacteriophage complex according to claim 3, it is characterized in that: described antioxidant be meant reduced glutathion or alpha-mercapto N-Propionylglycine and glucurolactone mixture etc. the weight mixture, the reduced glutathion consumption is the 0.5-4 parts by weight, and the consumption of alpha-mercapto N-Propionylglycine and glucurolactone mixture is the 100-140 parts by weight.
5. according to claim 1 or 2 any described sulbactam sodium bacteriophage complexes, it is characterized in that: the diameter of described liposome is below 150nm.
6. according to claim 1 or 2 any described sulbactam sodium bacteriophage complexes, it is characterized in that: described 'beta '-lactam antibiotic is meant avocin, Amoxicillin Sodium and cefoperazone sodium.
7. according to claim 1 or 2 any described sulbactam sodium bacteriophage complexes, it is characterized in that: the 10-40% that the sulbactam sodium of parcel and antibiotics account for sulbactam sodium and antibiotics gross weight respectively in the liposome.
8. sulbactam sodium bacteriophage complex according to claim 7 is characterized in that: the 20-30% that the sulbactam sodium of parcel and antibiotics account for sulbactam sodium and antibiotics gross weight respectively in the liposome.
9. the preparation technology of claim 1 or 2 any described sulbactam sodium bacteriophage complexes is characterized in that step is as follows:
1) gets described amount liposome, be dissolved in the phosphate buffer;
2) described amount antibiotic and described amount sulbactam sodium are joined in the liposome solutions, dissolve under the ultrasonic stirring condition, regulate pH value between 5.0-7.0;
3) ultrasonic stirring adds described amount antioxidant and described weight northylen ketopyrrolidine, and dissolving repeats ultrasonic Treatment, and obtaining described amount antibiotic and described amount sulbactam sodium is the solution of 10-40% by the liposome rate;
4) with behind the 0.22um membrane filtration of step 3) gained solution usefulness aperture, lyophilization obtains lyophilized powder.
10. according to the preparation technology of the described sulbactam sodium bacteriophage complex of claim 9, it is characterized in that step is as follows:
1) gets described amount liposome, be dissolved in the phosphate buffer;
2) described amount antibiotic and described amount sulbactam sodium are joined in the liposome solutions, dissolving is regulated pH value between 5.0-7.0;
3) ultrasonic stirring adds described amount antioxidant and described weight northylen ketopyrrolidine, and dissolving repeats ultrasonic Treatment, and obtaining described amount antibiotic and described amount sulbactam sodium is the solution of 20-30% by the liposome rate;
4) with behind the 0.22um membrane filtration of step 3) gained solution usefulness aperture, lyophilization obtains lyophilized powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006100759614A CN101062032B (en) | 2006-04-25 | 2006-04-25 | Sulbactam sodium bacteriophage complex and the preparing method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006100759614A CN101062032B (en) | 2006-04-25 | 2006-04-25 | Sulbactam sodium bacteriophage complex and the preparing method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101062032A true CN101062032A (en) | 2007-10-31 |
| CN101062032B CN101062032B (en) | 2011-06-08 |
Family
ID=38963452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2006100759614A Expired - Fee Related CN101062032B (en) | 2006-04-25 | 2006-04-25 | Sulbactam sodium bacteriophage complex and the preparing method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101062032B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103012429A (en) * | 2012-12-28 | 2013-04-03 | 吴秋萍 | Novel amoxicillin sodium compound and composition of amoxicillin sodium compound and sulbactam sodium compound |
| CN103142588A (en) * | 2013-04-09 | 2013-06-12 | 黑龙江省汇丰动物保健品有限公司 | Amoxicillin sodium sulbactam sodium for injection and preparation method of amoxicillin sodium sulbactam sodium |
| CN104586843A (en) * | 2014-12-25 | 2015-05-06 | 重庆福安药业(集团)股份有限公司 | Amoxicillin sodium sulbactam sodium compound pharmaceutical composition for injector and preparation process thereof |
| CN105853441A (en) * | 2016-04-05 | 2016-08-17 | 海南合瑞制药股份有限公司 | Cefoperazone sodium and sulbactam sodium composition |
| WO2017117882A1 (en) * | 2016-01-04 | 2017-07-13 | 四川制药制剂有限公司 | Pharmaceutical composition of piperacillin sodium and sulbactam sodium |
| CN107823154B (en) * | 2017-11-21 | 2021-02-19 | 上海金城素智药业有限公司 | Cefaclor preparation and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1623544A (en) * | 2003-12-01 | 2005-06-08 | 沈阳华泰药物研究有限公司 | Preparation of injection amoxicillin subaton |
-
2006
- 2006-04-25 CN CN2006100759614A patent/CN101062032B/en not_active Expired - Fee Related
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103012429A (en) * | 2012-12-28 | 2013-04-03 | 吴秋萍 | Novel amoxicillin sodium compound and composition of amoxicillin sodium compound and sulbactam sodium compound |
| CN103012429B (en) * | 2012-12-28 | 2014-12-31 | 吴秋萍 | Novel amoxicillin sodium compound and composition of amoxicillin sodium compound and sulbactam sodium compound |
| CN103142588A (en) * | 2013-04-09 | 2013-06-12 | 黑龙江省汇丰动物保健品有限公司 | Amoxicillin sodium sulbactam sodium for injection and preparation method of amoxicillin sodium sulbactam sodium |
| CN104586843A (en) * | 2014-12-25 | 2015-05-06 | 重庆福安药业(集团)股份有限公司 | Amoxicillin sodium sulbactam sodium compound pharmaceutical composition for injector and preparation process thereof |
| WO2017117882A1 (en) * | 2016-01-04 | 2017-07-13 | 四川制药制剂有限公司 | Pharmaceutical composition of piperacillin sodium and sulbactam sodium |
| CN105853441A (en) * | 2016-04-05 | 2016-08-17 | 海南合瑞制药股份有限公司 | Cefoperazone sodium and sulbactam sodium composition |
| CN105853441B (en) * | 2016-04-05 | 2018-11-27 | 海南合瑞制药股份有限公司 | A kind of cefoperazone sodium sulbactam sodium composition |
| CN107823154B (en) * | 2017-11-21 | 2021-02-19 | 上海金城素智药业有限公司 | Cefaclor preparation and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101062032B (en) | 2011-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101062032A (en) | Sulbactam sodium bacteriophage complex and the preparing method thereof | |
| CN1919363A (en) | Novel dialytic concentrating preparation | |
| CN1267220A (en) | Gelled composition | |
| CN1763093A (en) | Survivin mutant containing HIV transduction structural area and its preparation method and uses | |
| CN1879876A (en) | Neurotrophic factor slow release microsphere and its preparation method | |
| CN1896107A (en) | Cecropin A-magainin hybrid gene engineering bactericidal peptide | |
| CN1486177A (en) | Method and preparation for binding acetaldehyde in saliva, stomach and large intestine | |
| CN1529614A (en) | Method of reducing side effects of chemotherapy in cancer patient | |
| CN1840171A (en) | Nutrition liquid for chronic nephropathy and preparation method thereof | |
| CN1190186C (en) | Carbohydrate medical solution and sulphite stabilisator in multiple compartment container and use thereof | |
| CN1033000A (en) | The magnesium additive of nutrients, feed and medicine | |
| CN101036642A (en) | Ginkgolide B nanometric liposomes medicine and the preparing method thereof | |
| CN1868463A (en) | Slow-release prepn. contg. alpha-lipoic acid or its derivatives, and preparing method therefor | |
| CN1030527A (en) | Anti-coccidiosis composition | |
| CN1857288A (en) | Slow released compound preparation of glycyrrhizic acid and glycyrrhizinate and its preparing process | |
| CN101041024A (en) | Medicinal composition for treating tuberculosis and its preparing process | |
| CN1166402C (en) | Composite Chinese medicine with health care function | |
| CN1887271A (en) | Azithromycin liposome composition medicine and its prepn process | |
| CN1833655A (en) | Sodium triphosphate transfusion and its prepn. technique | |
| CN1084061A (en) | Agent for treating cataract and preparation method thereof | |
| CN1861626A (en) | Metallic salt kind medicine containing glycyrrhizic hypoglycyrrhizic or its derivant and preparation process thereof | |
| CN1907293A (en) | Combined medicine for treating lpneumonia and preparing process thereof | |
| CN1500487A (en) | Oral compound levocetirizine pseudoephedrine formulation and its preparation | |
| CN1927206A (en) | Lornoxicam composition for injection and preparation process thereof | |
| CN1093371A (en) | The treatment of gram-positive diseases of aquatic species |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: HU'NAN KANGDOU PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: LIU XIANGHUA Effective date: 20121114 Free format text: FORMER OWNER: CAI HAIDE Effective date: 20121114 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 410329 CHANGSHA, HUNAN PROVINCE TO: 426100 YONGZHOU, HUNAN PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20121114 Address after: The 426100 town Qiyang County of Hunan province Wu Day Road No. 1 Patentee after: Hunan Kangdu Pharmaceutical Co., Ltd. Address before: 410329 Liuyang biological pharmaceutical industry park Hunan Hunan Kang Yuan Pharmaceutical Co., Ltd. Patentee before: Liu Xianghua Patentee before: Cai Haide |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110608 Termination date: 20180425 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |